Su | Mo | Tu | We | Th | Fr | Sa |
---|---|---|---|---|---|---|
Su | Mo | Tu | We | Th | Fr | Sa |
---|---|---|---|---|---|---|
-
Jun 24, 2021
COVID-19 pandemic significantly impacted the DIAMOND study, leading to lower-than-anticipated enrolment and slower incidence of cardio-vascular events Independent study Executive Committee...
-
Jun 24, 2021
Abbas Hussain will take over as CEO of the Vifor Pharma Group on 16 August 2021 Succeeding Stefan Schulze, who has decided to step down and leave the company for personal reasons St. Gallen,...
-
May 6, 2021
Shareholders agreed to the Board of Directors’ recommendations for all proposed resolutions Election of Dr. Alexandre LeBeaut and Åsa Riisberg as Independent Directors Dividend of CHF 2.00 approved
-
Apr 30, 2021
Met primary efficacy endpoint of non-inferiority versus sevelamer carbonate Velphoro® effective in lowering and maintaining serum phosphorus level Safety profile of Velphoro® confirmed...
-
Apr 29, 2021
Topline data expected in the second half of 2021 St. Gallen, Switzerland, and Uniondale, NY, 29 April 2021 – Vifor Pharma and Angion Biomedica Corp. (NASDAQ: ANGN), today announced completion of...
-
Apr 28, 2021
CARE-HK in heart failure (HF) is the first global registry of around 5,000 patients with chronic HF who have or are at high risk for hyperkalemia (HK), in Europe and the US CARE-HK in HF is...
-
Mar 30, 2021
Companies have successfully submitted the EU regulatory application for marketing authorization for difelikefalin If approved, difelikefalin injection will be the first therapy available in Europe...
-
Mar 26, 2021
St. Gallen, Switzerland, 26 March 2021 – Vifor Pharma is pleased to announce that the Board of Directors will propose Åsa Riisberg for election to the Board at the Annual General Meeting on 6...
-
Mar 8, 2021
FDA has set Prescription Drug User Fee Act (PDUFA) target action date of 23 August 2021 If approved, KORSUVATM injection would be first therapy for treatment of pr uritus in hemodialysis patients...
-
Mar 3, 2021
Vifor Pharma delivers strong full year results 2020 with an EBITDA of 576 million Swiss Francs representing over 29% growth1 Net sales up 3.7% at constant exchange rates (CER), despite significant...